Clinical trials
Synucleinopathies clinical trials
Below are recruiting synucleinopathies clinical trials, each written for real people, not researchers. We’re tracking 15 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05527067Recruiting
Study of alpha-synuclein brain disease in patients and healthy people
This study follows people with a primary alpha-synuclein diagnosis and compares them with healthy controls. It aims to better understand this condition and may help researchers design better future tests and treatments.
Fuzhou, FujianAges 30–80 - NCT06460038RecruitingPhase 2
Medication study for constipation in Parkinson's
This study tests whether a medication called tenapanor can help relieve constipation in people with Parkinson's disease. If you have Parkinson's and have been struggling with constipation for at least 6 months, this trial may offer a new option to improve bowel regularity.
Waterloo, IowaAges 50–89 - NCT07324330Recruiting
Slowing cognitive decline with exercise in iRBD
This study tests if increasing physical activity can help slow down cognitive (thinking) decline in people with iRBD, a sleep disorder that often leads to Parkinson's or dementia. You'll use a smartphone and a FitBit to track your activity and receive coaching.
Bonn, North Rhine West-FaliaAges 50–80 - NCT01799915Recruiting
Study of causes and progression of synuclein-related nerve conditions
This study follows people over time to better understand “synucleinopathies,” which are conditions that affect the nervous system as it develops and progresses. You may be asked to return for visits and report symptoms, especially those that happen when you stand up.
Boston, MassachusettsAges 18 years+ - NCT07533799Recruiting
Swedish BioFINDER Sleep Study: Brain imaging in RBD and Parkinson's
This study examines brain changes in people with REM sleep behavior disorder (acting out dreams during sleep) and early Parkinson's disease using brain imaging scans. Researchers want to understand how sleep problems relate to Parkinson's development and find early warning signs.
MalmöAges 50–100 - NCT06996652RecruitingPhase 2
Study of adalimumab to delay Parkinson's symptoms in sleep disorder
This trial tests whether adalimumab, an immune system drug, helps people with REM sleep behavior disorder (a condition that may warn of Parkinson's disease) stay healthy longer. Participants will receive injections of the drug or a placebo to see if it prevents Parkinson's-related brain problems.
Los Angeles, CaliforniaAges 50–80 - NCT07589595RecruitingPhase 2
Donanemab for Early Cognitive Decline with Lewy Bodies
This study tests donanemab, an investigational drug designed to target amyloid proteins in the brain that may contribute to cognitive decline in people with early dementia with Lewy bodies. The trial aims to see if this treatment can slow cognitive decline and help preserve thinking and memory.
Chandler, ArizonaAges 55–85 - NCT06193252Recruiting
Exercising to slow Parkinson's in iRBD
This study tests whether a specific amount of exercise can slow the development of Parkinson's disease in people who have a sleep condition called iRBD. If you have iRBD and are not very active, researchers will help you start a personalized exercise program and track your progress with a smartphone app.
Nijmegen, GelderlandAges 50 years+ - NCT06596746Recruiting
Tracking markers for neurodegenerative diseases
This study tracks changes in people with Parkinson's disease, other movement disorders, or cognitive decline to find better ways to measure disease progression.
Cassino, FrosinoneAges 10 years+ - NCT06891703RecruitingEarly Phase 1
PET imaging study for Parkinson's and related conditions
This trial uses a new imaging agent (like a dye) to see signs of Parkinson's disease in the brain. If you have Parkinson's or a related condition like Lewy body dementia or multiple system atrophy, this scan may help researchers better understand these illnesses.
SolnaAges 20 years+ - NCT07187843Recruiting
Parkinson's type study: brain-first vs body-first
This study looks at how Parkinson's disease affects thinking, movement, and brain health differently depending on whether it starts in the brain or the body first. Participants will have tests and scans to track these differences over time.
Reggio EmiliaAges 18 years+ - NCT07640555RecruitingEarly Phase 1
Brain imaging study for Parkinson's and related movement disorders
This research study tests a new type of brain scan (called a PET scan) that may help detect early signs of Parkinson's disease and similar conditions. You'll receive the scan and may have a spinal tap to check for specific protein markers.
New Haven, ConnecticutAges 50–80 - NCT06745011Enrolling by invitation
Parkinson's signs in people with nerve damage
This study looks for early signs of Parkinson's disease in people who have nerve damage in their hands and feet (polyneuropathy) with no known cause, along with drops in blood pressure when standing up. It aims to understand if these early symptoms might predict future Parkinson's.
Aarhus, JutlandAges 18–85 - NCT05826457Enrolling by invitation
Study for early RBD as a possible Parkinson’s risk
This study looks at people with REM sleep behavior disorder (RBD), confirmed by a sleep test, who may be in the early “prodromal” stage before Parkinson’s or related diseases. It also enrolls healthy controls to compare results from brain and body testing to better understand who is at risk.
Los Angeles, CaliforniaAges 18 years+ - NCT03623672Enrolling by invitation
Study for early signs of Parkinson-related brain changes
This study enrolls people with idiopathic REM sleep behavior disorder, a sleep problem that can come before Parkinson’s disease or related conditions. It aims to better understand early (“prodromal”) changes so future treatments can be targeted earlier.
Sun City, ArizonaAges 18 years+
Hear when a new Synucleinopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for synucleinopathies?
- Yes. Clin2 currently lists 15 recruiting synucleinopathies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a synucleinopathies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a synucleinopathies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.